Languages
简体中文
繁體中文
English
日本語
한국어
Bahasa Indonesia
Tiếng Việt
Sign In
Send a Release
Products
News
Resources
Contact
Search
Search
Products
News
Resources
Contact
Overview
Content Creation
Distribution
Monitoring & Insights
Influencer Database
Falcon
All Products
Send a Release
News
Products
Resources
Contact
Overview
Latest
Regional
Mainland China
Japan
Korea
Indonesia
Malaysia
Singapore
Thailand
Vietnam
Australia
Industry
Auto & Transportation
Business Technology
Consumer Products & Retail
Consumer Technology
Energy
Entertainment & Media
Environment
Financial Services
General Business
Health
Heavy Industry & Manufacturing
Policy & Public Interest
Sports
Telecommunications
Travel
Food and Beverages
Advertising, Marketing and Media
Exhibition
Real Estate and Furniture
Trending Topics
Personnel Announcements
Earnings
New Technologies & New Products
Investment & Financing
Carbon Neutral
China International Consumer Products Expo
Olympics
Summer Event
Environmental, Social, Governance (ESG)
Sustainability
Embedded World
Belt & Road
Artificial Intelligence
IFA 2024
Holiday Season
Consumer Electronics Show (CES)
Canton Fair
Earth Day
Blockchain
Mother's Day
China International Import Expo
5G
Multimedia
Other Languages
Malaysian
Thai
Public Company News
Send a Release
Resources
Products
News
Contact
Overview
Beyond PR Blog
Media Coffee
Client Stories
White Papers
Events in APAC
Media Room
Send a Release
Contact
Products
Resources
News
Asia Pacific Offices
Request More Information
Alert / Newsletter Subscription
Our Presence on Social Media Sites
FAQs
Send a Release
Products
News
Resources
Contact
Send a Release
深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
Media Room
Latest News
Photo News
Photo News
Time
All
2024
2023
2022
2021
2020
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
2024-09-15 17:53
3122
Report
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment
2024-03-15 13:56
1614
Report
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
2023-11-10 08:00
1857
Report
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor
2023-08-23 10:51
1728
Report
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023
2023-06-07 08:00
2400
Report
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer
2023-04-21 09:06
2107
Report
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting
2023-04-19 08:29
1721
Report
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
2023-03-30 08:00
1731
Report
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma
2023-02-09 08:00
1825
Report
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
2022-10-26 14:26
2018
Report
ImmVira announced to launch the construction of Global R&D and Commercialization Base
2022-10-18 16:22
1166
Report
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation
2022-08-08 08:30
1542
Report
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
2022-07-21 08:00
1600
Report
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
2022-04-20 08:00
1679
Report
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
2022-03-02 09:07
1257
Report
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
2022-01-25 08:30
1533
Report
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
2022-01-19 08:30
1521
Report
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial
2021-08-11 10:45
1408
Report
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial
2021-08-06 19:50
2553
Report
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials
2021-07-19 08:30
1571
Report
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
2021-06-12 11:16
3192
Report
1
2
Share:
Share to wechat: